Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1306-2026Class II

Product Name: Lumipulse G -Amyloid 1-42-N Plasma Calibrators Model/Catalog Number: 235454 Software Version...

Fujirebio Diagnostics, Inc. / initiated 2025-12-11 / Open, Classified

Fujirebio Diagnostics, Inc. began a recall of Product Name: Lumipulse G -Amyloid 1-42-N Plasma Calibrators Model/Catalog Number: 235454 Software Version: Not Applicable Product Description: Lumipulse G... on . FDA classified it as Class II and gives the reason as "Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging...". As of , the recall status on record is Open, Classified.

Recall record

Recall number
Z-1306-2026
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
Fujirebio Diagnostics, Inc.
Product
Product Name: Lumipulse G -Amyloid 1-42-N Plasma Calibrators Model/Catalog Number: 235454 Software Version: Not Applicable Product Description: Lumipulse G -Amyloid 1-42-N Plasma Calibrators: The -Amyloid 1-42 plasma concentration of a specimen is automatically calculated from the calibration curve, which is automatically calculated from calibration data. The result of the calculation is reported in pg/mL. Lumipulse G -Amyloid 1-42-N Plasma Calibrators: Liquid (Frozen), 1 1.5 mL (4 Concentrations) CAL 1 0 pg/mL -Amyloid 1-42-N Plasma Calibrator CAL 2 30 pg/mL -Amyloid 1-42-N Plasma Calibrator CAL 3 100 pg/mL -Amyloid 1-42-N Plasma Calibrator CAL 4 1000 pg/mL -Amyloid 1-42-N Plasma Calibrator Contains Tris buffer with protein (bovine) and chemical stabilizers. Preservative: 0.1% ProClin 950. Component: Yes. Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio
Product code
SET Immunoassay Blood Test For Amyloid Pathology Assessment
Reason for recall
Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as having amyloid pathology associated with Alzheimer s disease (positive result) and/or requiring more clinical testing of that patient (indeterminate result).
FDA root cause
Under Investigation by firm
Action
On or about December 11, 2025 URGENT PRODUCT CORRECTION NOTIFICATION letters were sent to customers. Actions to be taken: - Immediately discontinue using the associated Lots listed above for the Lumipulse G pTau217/-Amyloid 1-42 Plasma Ratio. - Review this letter with your Medical Director to determine the appropriate course of action, including for any previously generated results, if applicable. - Notify your ordering physician or health care provider as appropriate. - The test results must be interpreted in conjunction with other diagnostic tools and clinical information. - Please retain this letter with your laboratory records and forward this leer to those who may have received this product.
Quantity in commerce
128 units
Distribution
US Nationwide distribution in the states of Arizona, California, Florida, Indiana, Kansas, Kentucky, Maryland, Massachusetts, Minnesota, New Jersey, Pennsylvania, Texas, Washington.
Product codes and lots
Model/Catalog Number: 235454; UDI-DI: 04987270235454; Lot Numbers: D8C6022U, D8C6044U;

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1306-2026
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1301-2026Class IIOngoingVoluntary: Firm initiated
Z-1302-2026Class IIOngoingVoluntary: Firm initiated
Z-1303-2026Class IIOngoingVoluntary: Firm initiated
Z-1304-2026Class IIOngoingVoluntary: Firm initiated
Z-1305-2026Class IIOngoingVoluntary: Firm initiated
Z-1306-2026Class IIOngoingVoluntary: Firm initiated
Z-1307-2026Class IIOngoingVoluntary: Firm initiated